Letter from the Editor


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1156.

Product Description

According to Datamonitor, leading specialty pharmaceutical companies are beginning to outgrow the traditional acquisition-only model as the size of the products required to continue their expansion puts them into greater competition with larger pharma companies and raises the price of licensing agreements.
Nicole Lamble, pharmaceutical analyst at Datamonitor Plc., says specialty pharma companies are increasingly looking upstream to fill pipeline gaps with their own R&D rather than acquisitions. But, this is not the only growth strategy available to them. Partnership networks, for example, will become more pivotal to growth and therapeutic foci will widen or change…